Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
China Rising Investment Conference (May 18, 2009)
http://www.chinarisingconference.com/presenting.html
The global market meltdown has created opportunities to invest in outstanding companies in what continues to be the fastest growing major economy in the world at historically unprecedented valuations.
Please join the China Rising Investment Conference to meet with the senior management of a wide range of growth companies from China in sectors including consumer staples, agriculture, pharmaceuticals, infrastructure, information technology, advanced materials, capital goods, and alternative energy.
Hear the top picks by the best informed analysts currently following Chinese equities. And get in-depth advice on successful China investing strategies from leading public and private equity investors active in China.
30 companies, from microcap to large cap
250 fund managers and investors
Presentations and one-on-one meetings
Analyst roundtable with top picks for 2009
Conference attendance is by invitation only.
Contact Info:
For investment professionals who are interested in attending the conference, please click here to register. We will process your request and get back to you with confirmation.
For individual investors, you are welcome to sign up to listen to webcast.
For company executives who are interested in presenting at the conference, please contact: Crocker Coulson (646) 213 1915 crocker.coulson@ccgir.com
For sponsorship opportunities, please contact Crocker Coulson (646) 213 1915 crocker.coulson@ccgir.com or Karen Ji (310) 954 1351 karen.ji@ccgir.com
Confirmed Presenting Companies:
...
Genesis Pharmaceuticals GNPH
?? a purchase is still another current option ??
http://streetstylz.blogspot.com/2008_06_01_archive.html
Sunday, June 22, 2008
Is NeoMedia Technologies For Sale?
NeoMedia Technologies, the global leader in camera-initiated barcode transactions for mobile devices, released an 8-K SEC filing last Monday which alluded to the potential sale of the company.
The filing states that during the next 18 months NeoMedia's CEO Iain McCready can earn a commission of up to 2.5% of sales proceeds for selling the company if the sale price is not less than $45M, with a commission cap set at a $200M sale price.
However, that's not to say that Iain can't sell NeoMedia for more than $200M. He can. Especially with a favorable patent review by the USPTO anticipated later this year.
NeoMedia Technologies has a suite of twelve issued patents covering the core concepts behind linking the physical world to the electronic world dating back to 1995. These patents cover various linkage methods including: Barcodes, RFID, Mag Stripe, Voice, and Other machine readable and keyed entry identifiers.
These patents were first licensed by Digital Convergence for $100M in 2000 to facilitate the launch of the :CueCat.
In 2001, NeoMedia Technologies formed a strategic alliance with Symbol, now owned by Motorola, and signed a worldwide agreement which gave Symbol the right to grant licenses to itself and third parties under NeoMedia's intellectual property. Symbol would later offer to buy NeoMedia's valuable patent portfolio in 2002 for $150M. The offer was declined however in favor of further developing the IP and growing the patent portfolio as a core component of NeoMedia's long-term growth and market strategy.
In 2005, Virgin Entertainment and NeoMedia Technologies entered into an extended licensing agreement, which saw Virgin license NeoMedia's patents through 2016.
There were even strong rumors that Microsoft was interested in purchasing NeoMedia back in 2005.
Flash forward to today, mobile barcode reading is an everyday part of the popular culture in Japan and Korea. The technology is just now beginning to emerge in Europe with North America not too far behind. With so many companies entering the mobile code reading space, and looking to carve out their niche, NeoMedia has positioned itself well with it's extensive patent portfolio and barcode technology, and will bring tremendous value to anyone interested in acquiring the company.
short-update :
http://shortsqueeze.com/?symbol=rz&submit=Short+Quote%99
Raser TechnologiesInc. $ 4.60
RZ
Short Interest (Shares Short) 7,922,400
Days To Cover (Short Interest Ratio) 20.1
Short Percent of Float 17.78 %
Short Interest - Prior 8,004,400
Short % Increase / Decrease -1.02 %
Short Squeeze Ranking™ -157
% From 52-Wk High ($ 11.79 ) -156.30 %
% From 52-Wk Low ($ 2.15 ) 53.26 %
% From 200-Day MA ($ 4.18 ) 9.13 %
% From 50-Day MA ($ 3.58 ) 22.17 %
Price % Change (52-Week) -43.90 %
Shares Float 44,550,000
Total Shares Outstanding 65,138,877
% Owned by Insiders 39.60 %
% Owned by Institutions 19.60 %
Market Cap. $ 299,638,834
Trading Volume - Today 1,038,006
Trading Volume - Average 394,100
Trading Volume - Today vs. Average 263.39 %
Earnings Per Share -0.44
PE Ratio
Record Date 2009-MarB
Sector Industrial Goods
Industry Industrial Electrical Equipment
Exchange NY
CTIC -
http://www.ilnuovomercato.it/newsmanager/setpageinm/ilnuovomercatoMM.aspx?articleid=15664&zoneid=1
Cell Therapeutics. Il Pixantrone ad un passo dall’approvazione
giovedì 26 marzo 2009 - 17:55
Il Pixantrone ad un passo dall’approvazione. Secondo indiscrezioni circolate nelle ultime ore già nei prossimi giorni potrebbe essere approvato il Pixantrone, farmaco antitumorale attivo contro il linfoma non hodgkin. Sulla scia delle voci circolate il titolo è arrivato a toccare a Wall Street un rialzo superiore al 200% su forti scambi. Secondo le indicazioni della stessa società la commercializzazione del Pixantrone potrebbe portare entro il 2014 ad un fatturato di 1 miliardo di dollari, anche se a detta degli analisti i numeri potrebbero essere molto più alti. Il colosso Novartis risulta tuttora titolare di un’opzione per negoziare una licenza mondiale in esclusiva per sviluppare e commercializzare il farmaco antitumorale Pixantrone.
http://babelfish.yahoo.com/translate_url?doit=done&tt=url&intl=1&fr=bf-home&trurl=http%3A%2F%2Fwww.ilnuovomercato.it%2Fnewsmanager%2Fsetpageinm%2FilnuovomercatoMM.aspx%3Farticleid%3D15664%26zoneid%3D1&lp=it_en&btnTrUrl=Translate
Cell Therapeutics. The Pixantrone to a step from the approval
26 thursdays March 2009 - 17:55
The Pixantrone to a step from the approval. According to indiscretions circulated in the last hours already in the next few days could be approved of the Pixantrone, active antitumor drug against the lymphoma not hodgkin. On the wake of the voices circulated the title it has succeeded in to touch to Wall Street a advanced rise to 200% on strong exchanges. According to the indications of the same society the commercialization of the Pixantrone could carry within 2014 to a turnover of 1 billion of dollars, even if to said of the analysts the numbers they could be very higher. The Novartis colossus still turns out titular of an option in order to negotiate a world-wide licence in exclusive right in order to develop and to commercialize the antitumor drug Pixantrone
schäm dich! HCKE (pfui!)
#8072 CETV -
http://seekingalpha.com/article/127643-cetv-sells-stake-to-time-warner-improves-risk-reward-tradeoff?source=feed
CETV Sells Stake to Time Warner, Improves Risk-Reward Tradeoff
by: Steve Birenberg March 24, 2009
Central European Media Enterprises (CETV), one of my long-time favorite stocks which I stupidly rode all the way down, soared on Monday following the announcement that it was selling a 31% stake to Time Warner (TWX) at a 20% premium to Friday's close. Apparently, I was not the only who believed that CETV had sunk to prices that deeply undervalued the company. Congratulations to Time Warner for taking advantage of unfortunate circumstances to move into the driver's seat of long-term control at a company with substantial upside when the global economy recovers.
With TWX effectively backstopping shareholders at $12, I have a hard time seeing downside in the stock below $10-11. As explained below, I can model further event driven upside in the short-term with long-term value of $30 once Eastern European economies show signs of renewed growth. The risk-reward trade-off has dramatically improved so I would be a buyer on any weakness off Monday's spike.
Here is a link to an extensive archive of my research on CETV chronicling a ride up to over $100 and back down to $5.
CETV also announced weak 1Q09 guidance. This is no surprise, but is below current analyst estimates. The ad markets in Eastern Europe froze early in 2009. Furthermore, currency compares are down 20-30% and the guidance is in US dollars. Finally, 1Q08 was unusually strong in a seasonally weak quarter due to a management plan to smooth seasonality by pulling advertising from 2Q to 1Q....
Full year guidance will be provided in May when the company reports 1Q. I still think they can get close to $200 million in EBITDA this year, particularly if Eastern European currencies continue their recent recovery (up 10-20% from lows). But that does not really matter as TWX is betting that the company can get to $300 million or much more within a few years in which case the 2009 figure is irrelevant now that TWX has backstopped the value of CETV.
Dilution is steep, but the current environment is unprecedented. If growth resumes, the stock can reach $30-40 in a few years pretty easily despite the dilution. In the short-term, look for announcements that would limit the cash flow outflows in Bulgaria and Ukraine this year. Finally, I hope the company buys back its converts at 50 cents on the dollar as that would be a great way to offset dilution by transferring enterprise value from debt holders to shareholders.
CETV will remain an event driven stock until fundamentals of Eastern European economies turnaround. Announcements on Bulgaria, Ukraine, or the convertibles can provide further upside in the near-term. In the long-term, $30-40 is very realistic once Eastern European economies resume growth. At $30 the company would have an enterprise value of $2.5 billion, hardly a stretch for a business that in 2008 reported adjusted EBITDA of about $370 million.
#9954 !! NEOM -
http://streetstylz.blogspot.com/2009/03/who-will-be-first-to-license-neomedias.html
Monday, March 23, 2009
Who Will Be First To License NeoMedia's Patents
The mobile code ecosystem has been a buzz ever since NeoMedia Technologies announced last month that the United States Patent and Trademark Office had ruled in favor of NeoMedia in the reexamination of its U.S. Patent No. 6,199,048 -- System And Method For Automatic Access Of A Remote Computer Over A Network.
NeoMedia currently has 30 active patents spanning 13 countries, with 29 additional patents pending. These patents cover various linkage methods including: Barcodes, RFID, Mag Stripe, Voice, and other machine readable and keyed entry identifiers.
According to NeoMedia's CEO Iain McCready, "A couple of competitors in the USA have already asked us for a free license but we can’t accept that. We are a business and so are they. In a reasonable manner, and at a fair price, we want to move forward with this. I am open to discussion and we want to be seen as fair. We want the whole mobile barcode market to succeed and the license fee model is tried and tested and it works. It can be as simple or as difficult as people want it to be and we aim to keep it simple. We have been working very very closely with both the GSMA and the OMA, and by being connected, the introduction of a license model can and will only succeed."
With the Google backed ShopSavvy and CompareEverywhere barcode applications making strong headway, and the recently launched Microsoft Tag reader carving out its niche, the mobile code ecosystem is quickly attracting major industry players.
Last week France's Mobile Tag announced that former NeoMedia CEO William "Chip" Hoffman had joined the company to head up their US operations. Mobile Tag uses mobile barcode technology patented by NeoMedia, and makes for a very likely patent licensee. Likewise with Google, Microsoft, Scanbuy and Upcode.
In keeping with its vision and commitment to developing an interoperable global ecosystem, NeoMedia is licensing its technology to foster innovation in the creation of exciting new mobile barcode applications and services.
NEOM...it holds and continues to rise (52 wk high!)
http://ih.advfn.com/p.php?pid=squote&symbol=NEOM
_bbb_ / bradford86
...
Change of Rules (25.01.2009):
NO more OTC/Pinkies, except those which are already listed.
New Stocks must be AMEX minimum, better NYSE / Nasdaq.
(#3406-3409)
;0) ax
11:46 a.m. FASB: Mark-to-Market guidance out in three weeks
http://www.marketwatch.com/
http://www.marketwatch.com/news/story/Lawmakers-urge-changes-mark-market/story.aspx?guid=%7B8F2783FB%2D3CDE%2D462F%2D827D%2DD47ABDA100A8%7D
Cool geothermal power coming to Anaheim
http://www.greenrightnow.com/kabc/2009/03/11/cool-geothermal-power-coming-to-anaheim/
Cool geothermal power coming to Anaheim
March 11th, 2009
By Marice Richter
Green Right Now
Anaheim, Ca., will become a leader in renewable energy when geothermal power operations begin as soon as this week.
Anaheim Public Utilities has teamed with Raser Technologies, a producer of geothermal power, to purchase 11 megawatts of geothermal power, enough electricity to supply about 10,000 homes in Anaheim, a city of about 345,000 residents.
The power will be transmitted to Anaheim from a new power plant in the south central desert of Utah. The plant, the first of its type, allows the electricity to be generated using steam from low to medium heat that is then mixed with a liquid substance. One the substance reaches a boiling point and converts to steam, it is channeled through a turbine to generate the power.
“Geothermal energy best meets the needs of the Utility,” said Marcie Edwards, general manager of Anaheim Public Utilities. “It’s cost-effective, reliable, abundant, and very importantly, produces zero emissions.”
While geothermal power isn’t new, this system is unique because it is able to produce power at a heated temperature of about 220 degrees as opposed to 450 degrees, which is the standard for most geothermal power systems, according to Raser Technologies officials. The low to medium temperature heat source - from thousands of feet below ground - is more widely available than the higher heat source.
Unlike wind and solar power, this type of geothermal power can be produced 24 hours a day, seven days a week.
“These types of green power are taking the place of fossil fuel plants that release emissions into the environment,” said Cameron Donahue, a spokesman for Hayden IR, an investment partner of Raser Technologies. “This also helps the city of Anaheim and the state of California — meet its goal of 20 percent renewable energy by 2015.”
Copyright © 2009 Green Right Now | Distributed by Noofangle Media
Cool geothermal power coming to Anaheim
http://www.greenrightnow.com/kabc/2009/03/11/cool-geothermal-power-coming-to-anaheim/
Cool geothermal power coming to Anaheim
March 11th, 2009
By Marice Richter
Green Right Now
Anaheim, Ca., will become a leader in renewable energy when geothermal power operations begin as soon as this week.
Anaheim Public Utilities has teamed with Raser Technologies, a producer of geothermal power, to purchase 11 megawatts of geothermal power, enough electricity to supply about 10,000 homes in Anaheim, a city of about 345,000 residents.
The power will be transmitted to Anaheim from a new power plant in the south central desert of Utah. The plant, the first of its type, allows the electricity to be generated using steam from low to medium heat that is then mixed with a liquid substance. One the substance reaches a boiling point and converts to steam, it is channeled through a turbine to generate the power.
“Geothermal energy best meets the needs of the Utility,” said Marcie Edwards, general manager of Anaheim Public Utilities. “It’s cost-effective, reliable, abundant, and very importantly, produces zero emissions.”
While geothermal power isn’t new, this system is unique because it is able to produce power at a heated temperature of about 220 degrees as opposed to 450 degrees, which is the standard for most geothermal power systems, according to Raser Technologies officials. The low to medium temperature heat source - from thousands of feet below ground - is more widely available than the higher heat source.
Unlike wind and solar power, this type of geothermal power can be produced 24 hours a day, seven days a week.
“These types of green power are taking the place of fossil fuel plants that release emissions into the environment,” said Cameron Donahue, a spokesman for Hayden IR, an investment partner of Raser Technologies. “This also helps the city of Anaheim and the state of California — meet its goal of 20 percent renewable energy by 2015.”
Copyright © 2009 Green Right Now | Distributed by Noofangle Media
NACEL Energy and the American Recovery and Reinvestment Act of 2009
http://ih.advfn.com/p.php?pid=nmona&cb=1236786375&article=36828708&symbol=NB%5ENCEN
DENVER, March 11 /PRNewswire-FirstCall/
NACEL Energy Corporation (OTC Bulletin Board: NCEN) (FRANKFURT: "4FC") ("NACEL Energy" or "Company"), a wind power company in business to generate clean, renewable energy, today provided guidance to shareholders and interested parties, concerning the impact of the American Recovery and Reinvestment Act of 2009 (the "Stimulus Legislation"), signed into law by President Obama in Denver, Colorado on February 25, 2009, on the Company's Blue Creek, Channing Flats, Swisher and Hedley Pointe wind power projects, all underway in the Texas Panhandle, as well as the Company's pipeline of new wind projects in feasibility, in three other States.
Under present Federal law, an income tax credit of 2.1 cents/kilowatt-hour, indexed for inflation, exists for the production of electricity from utility class wind turbines. This incentive, termed the renewable energy production tax credit (PTC), was created under the Energy Policy Act of 1992. The Stimulus Legislation includes a three-year extension of the PTC. Consequently, the 2.1 cents/kilowatt-hour tax credit may be applied to all NACEL Energy's existing and proposed wind power generation projects, through the new expiration date of December 31, 2012.
However, NACEL Energy believes that the most important aspect of the Stimulus Legislation is the new option to elect a 30% investment tax credit (ITC), up front, in lieu of the PTC. This option is available to NACEL Energy for all wind power generation facilities which it places in service in 2010, and also for facilities placed in service before 2013, if construction begins before the end of 2010.
Further, the Stimulus Legislation also allows NACEL Energy, in lieu of the PTC or the ITC, to elect to receive a direct grant from the Department of Treasury equal in amount to the ITC, being 30% of the construction cost of the applicable wind project. The Department of Treasury is required to pay the grant request within 60 days of the later of (i) the date of the Company's application which must be received before October 1, 2011, or (ii) the date that the specified Company wind facility commences commercial operations.
NACEL Energy Chief Executive Officer, Brian Lavery, stated:
"The impact of the American Recovery and Reinvestment Act on NACEL Energy's expected cash flow from our four Texas projects, now underway, is extremely positive. The Company will additionally endeavor to advance our three wind project opportunities in feasibility, in order to fully capitalize on the provisions of this new legislation."
About NACEL Energy Corporation (OTC BB: NCEN)
NACEL Energy is one of the first publicly-traded companies in America exclusively developing utility class wind power generation projects. NACEL Energy has commenced work at its Hedley Pointe, Swisher, Blue Creek and Channing Flats projects, all located in Texas, and currently anticipates 80 MW of new wind power upon their completion. NACEL Energy was founded in 2006 and successfully completed its IPO in December of 2007.
For more information visit our website http://www.nacelenergy.com/
NACEL Energy The WIND POWER COMPANY(TM)
Notice regarding Forward-Looking Statements
Statements in this press release relating to NACEL Energy's plans, strategies, economic performance and trends, projections of results of specific activities, and other statements that are not descriptions or historical facts may be forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995, Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934. Forward-looking information is subject to risks and uncertainties, and actual results could differ materially from those currently anticipated due to a number of factors, which include, but are not limited to, risk factors inherent in NACEL Energy's business. Forward-looking statements may be identified by words such as "should," "may," "will," "anticipate," "expect," "estimate," "intend" or "continue," or comparable words or phrases. This press release cautions that NACEL Energy must undertake and complete many steps in the development model before the generation of wind energy can commence. Among the numerous items which have to be completed in this regard include, without limitation, obtaining pertinent agreements and permits, construction of project facilities, satisfying financial requirements and other burdens. In addition, the full impact of the new legislation and its incentive provisions require the enactment of further regulations, which have not yet been proposed. Thus, the full impact and effect of the new legislation on NACEL Energy and its wind projects is not known at this time. Interested persons are encouraged to read the SEC reports of NACEL Energy, particularly its Annual Report on Form 10-KSB for the fiscal year ended March 31, 2008, and its Quarterly Report on Form 10-Q for the quarter ending December 31, 2008, for meaningful cautionary language disclosing why actual results may vary materially from those anticipated by management.
DATASOURCE: NACEL Energy Corporation
CONTACT: NACEL Energy Investor Services, 1-888-242-5848
Web Site: http://www.nacelenergy.com/
PLD -
http://ih.advfn.com/p.php?pid=nmona&cb=1236700753&article=36813557&symbol=NY^PLD
ProLogis Closes on $120 Million Portfolio Refinancing for ProLogis California Fund
DENVER, March 10 /PRNewswire-FirstCall/ -- ProLogis (NYSE:PLD), a leading global provider of distribution facilities and services, announced today that it has closed on a $120 million, ten-year, secured financing with a major life insurance company on behalf of the ProLogis California Fund. The financing has a loan-to-value of approximately 50 percent with 11 industrial properties located in the LA Basin and Inland Empire as security. The proceeds will be used to partially refinance a $176 million secured debt facility that was set to mature in March 2009 but has been extended to March 2010.
In November 2008, ProLogis announced a series of immediate, definitive actions and outlined a strategic plan to reduce debt, de-risk the development pipeline and right-size the company. The plan includes re-financing and/or renegotiating debt maturities on ProLogis' balance sheet and in its property funds, halting new development starts, shrinking the development pipeline, de-levering the balance sheet, and retaining capital through G&A cuts and a reduction of the dividend.
MarketWatch Hot Stocks: Financials (Video)
http://www.marketwatch.com/video/asset/marketwatch-hot-stocks-financials/B59DD672-AC3A-4DD2-BA2E-27F0286A5D2D
FITB - annual meeting
http://ih.advfn.com/p.php?pid=nmona&cb=1236699401&article=36815447&symbol=N^FITB
NOTICE OF ANNUAL MEETING OF SHAREHOLDERS
March 10, 2009
To the Shareholders of Fifth Third Bancorp:
You are cordially invited to attend the Annual Meeting of the Shareholders of Fifth Third Bancorp to be held at the Junior Ballroom, located on the third floor of the Duke Energy Center at 525 Elm Street, Cincinnati, Ohio on Tuesday, April 21, 2009 at 11:30 a.m. for the purposes of considering and acting upon the following:
1) Election of all members of the Board of Directors to serve until the Annual Meeting of Shareholders in 2010.
(2) The proposal described in the proxy statement to amend Article Fourth of the Articles of Incorporation to revise the terms of the authorized, unissued shares of Preferred Stock, without par value, available for issuance by Fifth Third Bancorp to provide greater flexibility in the terms of Preferred Stock that Fifth Third Bancorp may offer and sell in the future, and to clarify the ability of Fifth Third Bancorp to issue shares of Preferred Stock without stockholder approval in accordance with the terms of Ohio law. The proposed Amendment is attached as Annex 1 to the Proxy Statement and is incorporated therein by reference.
(3) The proposal described in the Proxy Statement to adopt the Amended and Restated Fifth Third Bancorp 1993 Stock Purchase Plan and the issuance of up to an additional 12,000,000 shares of Common Stock thereunder. The proposed plan is attached as Annex 2 to the Proxy Statement and is incorporated therein by reference.
(4) Approval of the appointment of the firm of Deloitte & Touche LLP to serve as the independent registered public accounting firm for the Company for the year 2009.
(5) An advisory vote to approve the compensation of the Company’s Named Executive Officers
(6) To vote on one or more proposals submitted by shareholders if properly presented at the Annual Meeting.
(7) Transaction of such other business that may properly come before the Annual Meeting or any adjournment thereof.
Shareholders of record at the close of business on February 27, 2009 will be entitled to vote at the Annual Meeting
RZ to Participate in Merrill Lynch’s Cleantech Leaders Conference
http://ih.advfn.com/p.php?pid=nmona&cb=1236355122&article=36698164&symbol=NY%5ERZ
Raser Technologies, Inc. (NYSE: RZ) announced today that Kraig Higginson, the Company’s Chairman, is scheduled to present at the Merrill Lynch Cleantech Leaders conference at 3:00 PM EDT on March 11, 2009, held at 4 World Financial Center in New York City. Merrill Lynch’s Cleantech Leaders conference is a multi-sector conference hosting leading companies who focus on advanced technologies and cleantech business practices.
The presentation will be webcast live and archived on the website http://www.veracast.com/webcasts/ml/cleantech09/45114118.cfm.
Management will be available for one-on-one meetings during the conference. Interested attendees may schedule the one-on-one meetings directly with Merrill Lynch’s representatives.
RZ to Participate in Merrill Lynch’s Cleantech Leaders Conference
http://ih.advfn.com/p.php?pid=nmona&cb=1236355122&article=36698164&symbol=NY%5ERZ
Raser Technologies, Inc. (NYSE: RZ) announced today that Kraig Higginson, the Company’s Chairman, is scheduled to present at the Merrill Lynch Cleantech Leaders conference at 3:00 PM EDT on March 11, 2009, held at 4 World Financial Center in New York City. Merrill Lynch’s Cleantech Leaders conference is a multi-sector conference hosting leading companies who focus on advanced technologies and cleantech business practices.
The presentation will be webcast live and archived on the website http://www.veracast.com/webcasts/ml/cleantech09/45114118.cfm.
Management will be available for one-on-one meetings during the conference. Interested attendees may schedule the one-on-one meetings directly with Merrill Lynch’s representatives.
GEOTHERMAL JOINS THE NEW ENERGIES THAT BEAT COAL OR SOON WILL
Thursday, March 05, 2009
http://newenergynews.blogspot.com/2009/03/geothermal-joins-new-energies-that-beat.html
RZ Completes Final Preparations to Begin Delivering Power to the City of Anaheim
http://ih.advfn.com/p.php?pid=nmona&cb=1236276712&article=36625343&symbol=NY%5ERZ
Raser Technologies, Inc. (NYSE: RZ), a leader in geothermal power generation, announced today that it has completed final preparations needed to transmit power to the city of Anaheim beginning as early as next week.
The commissioning date was extended while the local utility in Utah completed the installation of the SCADA equipment needed to monitor transmissions on the grid. Raser has already been supplying about 3.5 megawatts (MW) of sustained power generated at the plant to the local utility while final preparations were completed. Raser plans to ramp up the amount of power delivered to Anaheim over the next few weeks.
“We are very pleased with the progress that we have made to date and believe that commissioning of the plant has gone very much in line with expectations,” said Steven Brown, Executive Vice President of Raser. “While there may be minor modifications needed from time to time, the plant is now ready to complete its ramp up. We have operated all of the UTC units over an extended period and I have been very pleased with their performance as well as the level of dedication the team has shown to complete the work on the project. Once we have the final production well linked to the plant, we expect to be able to ramp up to the 10 to 11 MW net capacity. We expect to be ramped up to about 7 MW and begin sending the power to Anaheim by the end of next week.”
Brent M. Cook, CEO of Raser, said, “Raser is achieving something that has never been done before in the power generation industry, and in record time. Steve and his team have done a terrific job in putting together the first truly modular commercial geothermal power plant in such a short period of time. All of the generators and components within the plant have now been proven-out in operation and performed above our expectations. We look forward to completing the ramping up process and expect to be at full capacity within the next few weeks.”
RZ Completes Final Preparations to Begin Delivering Power to the City of Anaheim
http://ih.advfn.com/p.php?pid=nmona&cb=1236276712&article=36625343&symbol=NY%5ERZ
Raser Technologies, Inc. (NYSE: RZ), a leader in geothermal power generation, announced today that it has completed final preparations needed to transmit power to the city of Anaheim beginning as early as next week.
The commissioning date was extended while the local utility in Utah completed the installation of the SCADA equipment needed to monitor transmissions on the grid. Raser has already been supplying about 3.5 megawatts (MW) of sustained power generated at the plant to the local utility while final preparations were completed. Raser plans to ramp up the amount of power delivered to Anaheim over the next few weeks.
“We are very pleased with the progress that we have made to date and believe that commissioning of the plant has gone very much in line with expectations,” said Steven Brown, Executive Vice President of Raser. “While there may be minor modifications needed from time to time, the plant is now ready to complete its ramp up. We have operated all of the UTC units over an extended period and I have been very pleased with their performance as well as the level of dedication the team has shown to complete the work on the project. Once we have the final production well linked to the plant, we expect to be able to ramp up to the 10 to 11 MW net capacity. We expect to be ramped up to about 7 MW and begin sending the power to Anaheim by the end of next week.”
Brent M. Cook, CEO of Raser, said, “Raser is achieving something that has never been done before in the power generation industry, and in record time. Steve and his team have done a terrific job in putting together the first truly modular commercial geothermal power plant in such a short period of time. All of the generators and components within the plant have now been proven-out in operation and performed above our expectations. We look forward to completing the ramping up process and expect to be at full capacity within the next few weeks.”
Congress to Vote on 'Cap-and-Trade' Legislation by Summer
http://ih.advfn.com/p.php?pid=nmona&cb=1236276209&article=36619819&symbol=NB%5ENCEN
WASHINGTON, March 5 /PRNewswire/ -- Two weeks after President Obama challenged Congress to send him a bill that "places a market-based cap on carbon pollution and drives the production of more renewable energy," House and Senate leaders responded with an ambitious timetable for new "cap-and-trade" legislation, including a final Senate vote by the end of summer.
Under a cap-and-trade system a "price" for emitting pollution into the atmosphere is established but companies are able to freely trade their greenhouse gas emissions in an open market. Burning coal or natural gas to generate electric power becomes more expensive - and renewable sources of energy like wind and solar that much more competitive.
Rep. Henry Waxman (D-Calif.) chair of the Energy & Commerce Committee, said he intends to have a cap-and-trade bill ready by late June. Sen. Majority Leader Harry Reid (D-Nev.) promised comprehensive energy legislation including cap-and-trade laws will be put to a vote this August.
For wind power developers, cap-and-trade legislation is expected to lead to even faster growth in an industry already coming off its best year ever in 2008. Argus Research confirmed its buy rating on AES (NYSE:AES). AES operates Buffalo Gap, one of the largest wind farms in Texas. Monday analysts at Argus stated AES "continues to have strong growth prospects."
CNBC guest analyst Francis Gaskins has a buy rating on NACEL Energy (OTC Bulletin Board: NCEN) which has four wind projects underway in Texas. Gaskins' research note indicated NACEL "represents a unique opportunity for investors interested in exposure to the sector," and puts a $4 valuation on the Company.
The imminent passage of cap-and-trade laws likely means more solar PV manufacturers will acquire or develop their own power projects. Monday First Solar (NASDAQ:FSLR) bought OptiSolar's pipeline of utility scale projects. Rival SunPower (NASDAQ:SPWRA) announced its own plans for new solar power projects in Florida and California last year. Following First Solar's purchase Lazard issued a buy on the Company and raised its target price to $145.
Before the Bell Publishing LLC advises C.M. Biddick is a member of the Financial Industry Regulatory Authority (FINRA) CRD number 2382884
DATASOURCE: Before the Bell Green Energy Watch
CONTACT: Before the Bell Green Energy Watch, 1-888-249-3011
GEOTHERMAL JOINS THE NEW ENERGIES THAT BEAT COAL OR SOON WILL
Thursday, March 05, 2009
http://newenergynews.blogspot.com/2009/03/geothermal-joins-new-energies-that-beat.html
...to change the name of the Company to Jiangbo Pharmaceuticals, Inc.
http://ih.advfn.com/p.php?pid=nmona&cb=1236269978&article=36628075&symbol=NB^GNPH
INFORMATION STATEMENT
OF
GENESIS PHARMACEUTICALS ENTERPRISES, INC.
Middle Section, Longmao Street, Area A, Laiyang Waixiangxing Industrial Park
Laiyang City, Yantai, Shandong Province, People’s Republic of China 265200
THIS INFORMATION STATEMENT IS BEING PROVIDED
TO YOU BY THE BOARD OF DIRECTORS OF
GENESIS PHARMACEUTICALS ENTERPRISES, INC.
WE ARE NOT ASKING YOU FOR A PROXY
AND YOU ARE REQUESTED NOT TO
SEND US A PROXY
This Information Statement is being mailed or furnished to the shareholders of Genesis Pharmaceuticals Enterprises, Inc., a Florida corporation (the “Company”), in connection with the authorization of the corporate action described below by the Company’s Board of Directors at a telephonic meeting held on February 12, 2009, and the subsequent approval of such corporate action by the written consent, dated March 3, 2009, of those shareholders of the Company entitled to vote shares of the Company’s common stock, par value $.001 per share (the “Common Stock”) representing at least a majority of the outstanding voting stock of the Company on such date entitled to vote with respect to such corporate action. Accordingly, all necessary corporate approvals required pursuant to the Florida Business Corporation Act (“FBCA”) and the Company’s articles of incorporation and bylaws in connection with the matters referred to herein have been obtained. This Information Statement is furnished solely for the purpose of informing the shareholders of the Company, in the manner required under the Securities Exchange Act of 1934, as amended (the “Exchange Act”) and Section 607.0704 of the FBCA, of this corporate action before it takes effect.
This Information Statement will be mailed or furnished to the shareholders of record of the Company on March 3, 2009. The Information Statement is first being mailed or furnished to the shareholders of the Company on or about March __, 2009, and the amendments described herein shall not become effective until at least 20 days thereafter.
ACTIONS BY BOARD OF
DIRECTORS
AND
CONSENTING SHAREHOLDERS
At a telephonic meeting held on February 12, 2009, the Board of Directors adopted a resolution to amend the Company’s articles of incorporation to change the name of the Company to Jiangbo Pharmaceuticals, Inc. (the “Name Change Amendment”). A copy of the Board minutes are attached hereto as APPENDIX A. The action taken by the Board of Directors with respect to the Name Change Amendment was subsequently approved by the written consent of the Company’s shareholders entitled to vote a majority of the shares of Common Stock then outstanding on March 3, 2009, a copy of which is attached as APPENDIX B: A copy of the Name Change Amendment is attached hereto as APPENDIX C.
...
Name Change Amendment
The Company’s articles of incorporation will be amended by striking out Article I and replacing it with the following new Article I.
“The name of the corporation is Jiangbo Pharmaceuticals, Inc.”
Purpose of Name Change Amendment
The purpose of changing the Company’s name to Jiangbo Pharmaceuticals, Inc. is to provide better identification of the Company’s established brand name in the People’s Republic of China. The Board believes that the proposed change of name of the Company is in the best interests of the Company and its shareholders.
Effective Date
Under applicable federal securities laws, the Name Change Amendment cannot be effective until at least 20 calendar days after this Information Statement is distributed to the Company’s shareholders. The Name Change amendment will become effective upon filing with the Secretary of State of Florida. It is anticipated that the foregoing will take place 20 calendar days after distribution of this Information Statement to the Company’s shareholders.
Dissenters’ Rights of Appraisal
The FBCA does not provide for dissenters’ or appraisal rights in connection with the change of the Company’s name.
FITB -
02/27/2009
Num / Time / Price / Size / Bid / Ask / Buy / Sell
84038 / 16:00:03 / 2.11 / 3.906.048 / 2.09 / 2.1 / 3.906.048 / -
...does someone know more than others?
http://www.mffais.com/fitb.html
http://shortsqueeze.com/?symbol=fitb&submit=Short+Quote%99
Fifth Third Bancorp $ 2.11
FITB
Short Interest (Shares Short) 39,143,800
Days To Cover (Short Interest Ratio) 1.0
Short Percent of Float 6.82 %
Short Interest - Prior 36,228,800
Short % Increase / Decrease 8.05 %
Short Squeeze Ranking™ -6
% From 52-Wk High ($ 24.88 ) -1079.15 %
% From 52-Wk Low ($ 1.01 ) 52.13 %
% From 200-Day MA ($ 9.47 ) -348.82 %
% From 50-Day MA ($ 3.32 ) -57.35 %
Price % Change (52-Week) -90.90 %
Shares Float 573,970,000
Total Shares Outstanding 577,486,544
% Owned by Insiders 2.31 %
% Owned by Institutions 81.70 %
Market Cap. $ 1,218,496,608
Trading Volume - Today 47,684,174
Trading Volume - Average 38,862,100
Trading Volume - Today vs. Average 122.70 %
Earnings Per Share
PE Ratio
Record Date 2009-FebB
Sector Financial
Industry Regional - Midwest Banks
Exchange NAS
PWAV - back to introduction
ANPI receives approval for Quill(TM) SRS PDO, MONODERM(TM) ...
http://ih.advfn.com/p.php?pid=nmona&cb=1235656119&article=36423675&symbol=N^ANPI
Angiotech receives approval for Quill(TM) SRS PDO, MONODERM(TM) and Nylon product lines for sale in Canada
VANCOUVER, Feb. 26 /PRNewswire-FirstCall/ -- Angiotech Pharmaceuticals, Inc. (NASDAQ: ANPI; TSX: ANP), a global specialty pharmaceutical and medical device company, today announced that it has received 510(k) clearance to begin marketing the Quill(TM) SRS Polydioxanone (PDO), MONODERM(TM) and Nylon product lines in Canada.
"With the approval of the PDO, MONODERM(TM) and Nylon product lines in Canada, we can further extend the global reach of this next-generation suture product beyond the U.S. and Europe," said Dr. William Hunter, President and CEO of Angiotech.
Quill(TM) SRS PDO is a longer-lasting absorbable suture, which is typically used for deeper tissue closures while Quill(TM) SRS MONODERM(TM) is made from a rapidly resorbing polymer and intended primarily for superficial wound closure applications and soft tissue approximation where use of an absorbable suture is appropriate. The monofilament Quill(TM) SRS Nylon is a polyamide suture indicated for use in soft tissue approximation excluding closure of the epidermis.
Quill(TM) SRS PDO, MONODERM(TM) and Nylon product lines have both been previously approved for sale in the U.S. and Europe.
About the Quill(TM) Self-Retaining System (SRS)
Quill(TM) SRS represents a revolutionary technology in wound closure made possible by bidirectional fixation within the wound. Its patented design allows the surgeon to begin closure at the midpoint of the wound and suture in two directions from the midpoint. Barbs within the Quill(TM) SRS distribute tension across the wound and eliminate the need for knots.
...
http://shortsqueeze.com/?symbol=anpi&submit=Short+Quote%99
Angiotech Pharmaceuticals Inc. $ 0.28
ANPI
Short Interest (Shares Short) 363,700
Days To Cover (Short Interest Ratio) 2.0
Short Percent of Float %
Short Interest - Prior 834,000
Short % Increase / Decrease -56.39 %
Short Squeeze Ranking™
% From 52-Wk High ($ 3.49 ) -1141.99 %
% From 52-Wk Low ($ 0.10 ) 64.41 %
% From 200-Day MA ($ 0.61 ) -117.08 %
% From 50-Day MA ($ 0.37 ) -31.67 %
Price % Change (52-Week) -91.10 %
Shares Float
Total Shares Outstanding 85,121,983
% Owned by Insiders %
% Owned by Institutions %
Market Cap. $ 23,919,277
Trading Volume - Today 131,788
Trading Volume - Average 178,600
Trading Volume - Today vs. Average 73.79 %
Earnings Per Share -8.15
PE Ratio
Record Date 2009-FebB
...Our Economic Recovery 'Begins With Energy'
http://ih.advfn.com/p.php?pid=nmona&cb=1235572006&article=36405053&symbol=NB%5ENCEN
Pres. Obama to Nation - Our Economic Recovery 'Begins With Energy'
WASHINGTON, Feb. 25 /PRNewswire/ -- President Obama's first speech to a Joint Session of Congress last night was almost entirely devoted to the troubled economy. Amid a deepening recession Obama described the $787 Billion stimulus as one of the bold steps his five week old administration is implementing to turn the US economy around.
In the speech, Obama vowed to spend $15 billion a year to develop renewable energy. "We know the country that harnesses the power of clean, renewable energy will lead the 21st century," he said. The administration's Secretary of Energy, Stephen Chu, announced on Monday an immediate fast-tracking of all applications from wind and solar companies for stimulus dollars to kick-start the construction of more projects.
Assuming wind companies receive the lion's share of stimulus dollars (wind power accounted for 95% of the renewable energy built over the last five years), the stimulus is expected to lead to the construction of 30,000-megawatts of additional capacity, according to Hugh Wynne, an analyst at Bernstein Research - enough new wind power to supply 9 million American homes.
Wind farm developer NACEL Energy (OTC:NCEN) (BULLETIN BOARD: NCEN) CEO Brian Lavery said, "We ran the numbers and the impact as we understand the new stimulus incentives for wind power are really quite significant." NACEL has four wind power projects underway in the Texas Panhandle. Advisory Research has a positive rating on NACEL and a $3.07 valuation.
Accelerating construction of wind farms is also expected to lead to a recovery in the turbine market in the second half of 2009. In recent months manufacturers General Electric (NYSE:GE) and Vestas (Pink Sheets: VWDRY), as well as companies which supply the carbon fiber for turbine blades such as Hexcel (NYSE:HXL) and Zoltek (NASDAQ:ZOLT), have all experienced slowing demand. Yesterday KeyBanc Capital Markets announced a new buy rating on Hexcel and a $10 valuation.
Before the Bell Publishing LLC advises C.M. Biddick is a member of the Financial Industry Regulatory Authority (FINRA) CRD number 2382884
Contact:
1-888-249-3011
DATASOURCE: Before the Bell Green Energy Watch
CONTACT: Before the Bell(TM) Green Energy Watch, 1-888-249-3011
NEW ENERGY WIRES, THE PLAN
Monday, February 23, 2009
The American Society of Civil Engineers gave the U.S. transmission infrastructure a D+. That’s the transmission infrastructure on which President Obama wants to double U.S. New Energy capacity. Think about that next time the lights flicker.
Former CIA Direction R. James Woolsey recently observed that it would be very challenging to INTENTIONALLY design a transmission system as brittle and vulnerable as the present U.S. transmission system. That’s the transmission system Silicon Valley’s ambitious information technology mavens want to make much smarter. Think about that next time there's a blackout somewhere that takes days to rectify.
There are almost 300,000 megawatts of wind projects waiting for access to the national grid. In California, 13,000 megawatts of solar power plants are waiting to connect. Think about that next time a threat of rolling brownouts is announced.
The New Energy industries are pushing for a whole new approach to transmission. Green Power Superhighways: Building a Path to America’s Clean Energy Future describes what they want and need. (For a recent assessment of an opposing point of view, see DOES BIG NEW ENERGY NEED BIG NEW TRANSMISSION?)
New Energy industry leaders are not calling for specific legislation. They’re not demanding specific sites. This is what American Wind Energy Association CEO Denise Bode called “a vision statement” focusing on 3 points: (1) More national planning, (2) more local and regional interconnection planning, and (3) a fair way to share costs and benefits.
... http://newenergynews.blogspot.com/2009/02/new-energy-wires-plan.html
Lehman To Spin Out Venture Cap Arm
02/24/09 - 03:37 AM EST
http://www.thestreet.com/story/10465711/1/lehman-to-spin-out-venture-cap-arm-report.html?puc=_tscrss
...added some to portfolio ...
;0) http://www.finanznachrichten.de/nachrichten-2009-02/13177822-sinopec-china-firms-consider-chemtura-assets-report-020.htm
Sinopec, China firms consider Chemtura assets-report
HONG KONG, Feb 23 (Reuters) - Sinopec (News) and other Chinese firms are reviewing the $1 billion worth of assets offered for sale by U.S. chemical maker Chemtura Corp (News), the South China Morning Post reported.
China National Chemical Corp and state oil trader Sinochem Corp are assessing the financial details of the assets, the paper said.
Chemtura said on Feb 10 it was considering selling some assets in order to pay back its debt due in July this year and that it plans to reduce inventories.
A buyer will have to be selected by the end of next month to give time to close the deal before the debt becomes due, the report said.
(Reporting by Nerilyn Tenorio; Editing by Ken Wills) Keywords: SINOPEC/CHEMTURA ASSETS
(nerilyn.tenorio@thomsonreuters.com; 852-28436441)
COPYRIGHT
Copyright Thomson Reuters 2009. All rights reserved.
The copying, republication or redistribution of Reuters News Content, including by framing or similar means, is expressly prohibited without the prior written consent of Thomson Reuters.
pre-market $1.75 - $2.30 !!!
NCX Secures $150 Million In New Financing
http://finance.yahoo.com/news/NOVA-Chemicals-Secures-150-bw-14434558.html
* Sunday February 22, 2009, 10:43 pm EST
CALGARY, Alberta--(BUSINESS WIRE)--NOVA Chemicals today announced that the Company has secured $150 million in new financing. The $150 million exceeds the February 28, 2009, new financing condition agreed to by the Company as part of the earlier announced financial covenant relief. The new financing is a revolving credit facility with Export Development Canada (EDC), and a syndicate of three Canadian banks.
“This is a very big step toward ensuring NOVA Chemicals’ financial position remains solid through this challenging period. We are particularly pleased to add EDC as a new lender to our financing mix,” said Larry MacDonald, Chief Financial Officer.
NOVA Chemicals produces plastics and chemicals that are essential to everyday life. Our employees develop and manufacture materials for customers worldwide that produce consumer, industrial and packaging products. NOVA Chemicals works with a commitment to Responsible Care® to ensure effective health, safety, security and environmental stewardship. Company shares are traded on the Toronto and New York stock exchanges as NCX.
Visit NOVA Chemicals on the Internet at www.novachemicals.com.
... -
http://ih.advfn.com/p.php?pid=nmona&cb=1235291876&article=36358711&symbol=N
"CTI continues to believe in the value of Zevalin as a commercially attractive product and effective form of cancer therapy; however, with the impressive clinical trial results for pixantrone and given the company's need for operating capital, we are compelled to exercise our option and focus our resources on pixantrone..."
...with Exercises Its Option to Sell Interest in Zevalin Joint Venture CTIC will not profit from Zevalin and that date 04/02/09 became unfortunately uninteresting therefore!
?? this is correctly understood ??
*****************************************************************
About Pixantrone
CTI expects to begin submission of a rolling New Drug Application (NDA) and request priority review for pixantrone to treat relapsed aggressive non- Hodgkin's lymphoma ( NHL) in the first quarter of 2009. If granted priority review a decision on the NDA could occur before the end of 2009.
The study received Special Protocol Assessment approval from the U.S. Food and Drug Administration (FDA) in 2004, and pixantrone has received fast track designation for this indication.
http://ih.advfn.com/p.php?pid=nmona&cb=1235293199&article=36307339&symbol=N^CTIC
CTIC Exercises Its Option to Sell Interest in Zevalin Joint Venture
http://ih.advfn.com/p.php?pid=nmona&cb=1235291876&article=36358711&symbol=N^CTIC
Cell Therapeutics Exercises Its Option to Sell Interest in Zevalin Joint Venture to Spectrum Pharmaceuticals for $18 Million
CTI to focus on Pixantrone and OPAXIO Approval and Commercialization
SEATTLE, Feb. 20 /PRNewswire-FirstCall/ -- Cell Therapeutics, Inc. (CTI) (Nasdaq and MTA: CTIC) announced today that it exercised its option to sell its 50% ownership interest in the Zevalin joint venture to Spectrum Pharmaceuticals, Inc. (Spectrum) for $18 million. CTI and Spectrum established a joint venture in December 2008 to develop and commercialize Zevalin. At that time CTI contributed all of the Zevalin related assets to the joint venture and sold to Spectrum a 50% membership interest in the joint venture for $15 million, plus certain milestone payments.
The Company will focus its resources on the approval of pixantrone for relapsed aggressive non-Hodgkin's lymphoma (NHL) and OPAXIO for non-small cell lung and ovarian cancer. CTI estimates that as a result of the sale of the Zevalin interest it will reduce expenses by approximately $15 million annually from activities previously associated with Zevalin while providing CTI with non-dilutive source of operating capital.
"CTI continues to believe in the value of Zevalin as a commercially attractive product and effective form of cancer therapy; however, with the impressive clinical trial results for pixantrone and given the company's need for operating capital, we are compelled to exercise our option and focus our resources on pixantrone," noted James Bianco, MD, CEO of CTI. "CTI has been proud to have provided Zevalin to patients since we acquired it in December, 2007 and having the foresight to bring the first line consolidation for indolent NHL data to the FDA for potential label expansion in the front line consolidation setting. With the progress we made in removing many of the barriers that prevent its more widespread use, we are confident Spectrum will be able to ultimately make Zevalin a commercially attractive product."
At the closing of the sale of CTI's 50% membership interest in the joint venture to Spectrum, CTI will receive $6 million, with the remainder of the $18 million to be paid within 90 days following such closing. The closing of the sale option transaction is contingent upon the satisfaction of certain closing conditions, including the delivery of a legal opinion from counsel to CTI, as specified in the operating agreement for the Zevalin joint venture. CTI believes that it will be in a position to promptly satisfy all of the closing conditions.
About Zevalin(R)
Zevalin(R) (Ibritumomab Tiuxetan) is a form of cancer therapy called radioimmunotherapy and is indicated as part of the Zevalin therapeutic regimen for treatment of relapsed or refractory, lowgrade or follicular B-cell non-Hodgkin's lymphoma, including patients with rituximab refractory follicular NHL. Zevalin is also indicated, under accelerated approval, for the treatment of relapsed or refractory, rituximab-naive, low-grade and follicular NHL based on studies using a surrogate endpoint of overall response rate. It was approved by the FDA in February of 2002 as the first radioimmunotherapeutic agent for the treatment of NHL.
Rare deaths associated with an infusion reaction symptom complex have occurred within 24 hours of rituximab (Rituxan(R)) infusions. Yttrium-90 Zevalin administration results in severe and prolonged cytopenias in most patients. Severe cutaneous and mucocutaneous reactions have been reported. The most serious adverse reactions of the Zevalin therapeutic regimen were primarily hematologic, including neutropenia, thrombocytopenia and anemia. Infusion-related toxicities were associated with pre-administration of rituximab. The risk of hematologic toxicity correlated with the degree of bone marrow involvement prior to Zevalin therapy. Myelodysplasia or acute myelogenous leukemia was observed in 2 percent of patients (8 to 34 months after treatment). Zevalin should only be used by health care professionals qualified by training and experience in the safe use of radionuclides.
Patients and healthcare professionals can visit http://www.zevalin.com/ for more information.
About Non-Hodgkin's Lymphoma
Non-Hodgkin's lymphoma (NHL) is caused by the abnormal proliferation of white blood cells and normally spreads through the lymphatic system, a system of vessels that drains fluid from the body. NHL can be broadly classified into two main forms - aggressive NHL, a rapidly spreading acute form of the disease, and indolent NHL, which progresses more slowly. According to the National Cancer Institute's SEER database there were nearly 400,000 people in the U.S. with NHL in 2004. The American Cancer Society estimates that in the United States 66,120 people are expected to be diagnosed with NHL in 2008. Additionally, approximately 19,160 are expected to die from this disease in 2008.
About Cell Therapeutics, Inc.
Headquartered in Seattle, CTI is a biopharmaceutical company committed to developing an integrated portfolio of oncology products aimed at making cancer more treatable. For additional information, please visit http://www.celltherapeutics.com/.
This press release includes forward-looking statements that involve a number of risks and uncertainties, the outcome of which could materially and/or adversely affect actual future results. Specifically, the risks and uncertainties that could affect the development of Zevalin include risks associated with preclinical and clinical developments in the biopharmaceutical industry in general and with Zevalin in particular including, without limitation, the potential for Zevalin FIT data to be acceptable to the FDA for this expanded indication or any other indication, the determinations by regulatory, patent and administrative governmental authorities, competitive factors, technological developments, and costs of developing, producing and selling Zevalin. There is also a risk that even if label expansion of Zevalin is approved, it may not result in a significant market increase for the drug due to the presence of other treatment options, failure to gain market acceptance and other factors. Additionally, the closing of the sale option and receipt of the purchase price assumes that the company will be able to satisfy all of the closing conditions and that Spectrum fulfills its legal obligations to timely deliver the purchase price. Disposition of our interest in Zevalin may not reduce our expenses to the extent as currently projected. You should also review the risk factors listed or described from time to time in the Company's filings with the Securities and Exchange Commission including, without limitation, the Company's most recent filings on Forms 10-K, 8-K, and 10-Q. Except as may be required by law, CTI does not intend to update or alter its forward-looking statements whether as a result of new information, future events, or otherwise.
Media Contact: Dan Eramian T: 206.272.4343 C: 206.854.1200 E: http://www.celltherapeutics.com/press_room
Investors Contact: Ed Bell T: 206.272.4345 Lindsey Jesch Logan T: 206.272.4347 F: 206.272.4434 E: http://www.celltherapeutics.com/investors
DATASOURCE: Cell Therapeutics, Inc.
CONTACT: Media, Dan Eramian, +1-206-272-4343, C, +1-206-854-1200,
, or Investors, Ed Bell, +1-206-272-4345, or Lindsey Jesch
Logan, +1-206-272-4347, F, +1-206-272-4434, , all of Cell
Therapeutics, Inc.
Web Site: http://www.celltherapeutics.com/
CTIC - Phase III safety data underscores clinical benefit of pixantrone
http://ih.advfn.com/p.php?pid=nmona&cb=1235291876&article=36307339&symbol=N^CTIC
Compared to Standard Therapies, Pixantrone Decreases Time to Achieve Complete Remission by 47% in Relapsed Aggressive Non-Hodgki
Phase III safety data underscores clinical benefit of pixantrone
SEATTLE, Feb. 18 /PRNewswire-FirstCall/ -- Cell Therapeutics, Inc. (Nasdaq and MTA: CTIC) announced today that updated safety and efficacy data from the phase III trial of pixantrone provides further support for a robust clinical benefit for pixantrone when used as single agent therapy in the treatment of multiple relapsed aggressive non-Hodgkin's lymphoma (NHL). On an intent-to-treat analysis, pixantrone recipients who achieved a complete remission did so during the first 2 cycles of therapy, compared to 4 cycles among standard chemotherapy recipients, (1.9 months vs. 3.6 months, pixantrone vs. standard chemotherapy). The duration of response in the patients was similar in the 37% of pixantrone patients who had either a partial or complete response compared to the 14% of comparator patients with a major response. However, the overall progression free survival (PFS) was significantly longer in the pixantrone arm (4.7 months vs. 2.6 months, hazard ratio = 0.6; p = 0.0074, pixantrone vs. standard chemotherapy). Thirty-two percent (32%) of pixantrone patients received all 6 cycles of therapy, with 84% receiving 5 of 6 cycles of treatment. Pixantrone recipients had a low incidence of severe neutropenia complicated by either fever or documented infections, or severe vomiting or diarrhea. Pixantrone patients also experienced a low incidence of hair loss, a very common side effect of other drugs in this class. Overall, the incidence of serious adverse events was similar between pixantrone and the control arm. The pixantrone patients had a higher incidence of leucopenia and neutropenia and numerically more severe cardiac events (4 vs 2) than in the control arm. Disease progression reported as an adverse event was less frequent in the pixantrone than in the control arm (1.5% vs. 13.4%).
"We were impressed to see that 84% of patients received at least 5 cycles of pixantrone therapy with a median total dose of 1,475 mg, despite having had significant prior therapy with doxorubicin, an agent in a similar class with cumulative cardiotoxicity," noted Jack Singer, M.D., Chief Medical Officer at CTI. "The rapid time-to-response data coupled with the relatively low incidence of traditional anthracycline toxicities and a safety profile that compares favorably to standard chemotherapy, positions pixantrone to live up to the promise of providing patients with relapsed aggressive NHL a meaningful clinical benefit."
CTI announced in November 2008 that it had achieved the primary efficacy endpoint of its phase III EXTEND (PIX301) trial of pixantrone (BBR2778). Patients randomized to treatment with pixantrone achieved a high rate of confirmed and unconfirmed complete remissions compared to patients treated with standard chemotherapy (14/70 (20.0%) for pixantrone arm compared to 4/70 (5.7%) for the standard chemotherapy arm, p = 0.02). No patient (0%) in the standard chemotherapy arm achieved a confirmed complete remission compared to 8/70 (11%) of pixantrone recipients.
CTI expects to begin submission of a rolling New Drug Application (NDA) and request priority review for pixantrone to treat relapsed aggressive non- Hodgkin's lymphoma ( NHL) in the first quarter of 2009. If granted priority review a decision on the NDA could occur before the end of 2009.
The study received Special Protocol Assessment approval from the U.S. Food and Drug Administration (FDA) in 2004, and pixantrone has received fast track designation for this indication.
About Pixantrone
Pixantrone (BBR 2778), a DNA intercalating antitumor agent that contains an aza-anthracenedione molecular structure, differentiating it from anthracycline chemotherapy agents, was discovered by our scientists in Bresso, Italy. Pixantrone is a novel DNA major groove binder that contains an aza- anthracenedione molecular structure, differentiating it from anthracycline chemotherapy agents. Anthracyclines have been shown to be very active clinically in a number of tumor types, such as lymphoma, leukemia, and breast cancer. For these diseases, anthracycline-containing chemotherapy regimens are effective in first-line (initial) treatment. However, they may cause cumulative heart damage that limits lifetime dosage and does not allow for retreatment. Pixantrone has been designed to reduce the potential for heart damage compared to currently available anthracyclines or anthracenediones without a loss in anti-tumor or immunomodulatory activities.
About Cell Therapeutics, Inc.
Headquartered in Seattle, CTI is a biopharmaceutical company committed to developing an integrated portfolio of oncology products aimed at making cancer more treatable. For additional information, please visit http://www.celltherapeutics.com/.
Sign up for email alerts and get RSS feeds at our Web site, http://www.celltherapeutics.com/investors_news.htm
This press release includes forward-looking statements that involve a number of risks and uncertainties, the outcome of which could materially and/or adversely affect actual future results. Specifically, the risks and uncertainties that could affect the development of pixantrone include risks associated with preclinical and clinical developments in the biopharmaceutical industry in general and with pixantrone in particular including the potential failure of pixantrone to prove safe and effective for treatment of relapsed aggressive NHL as determined by the FDA, the Company's ability to continue to raise capital as needed to fund its operations, competitive factors, technological developments, costs of developing, producing and selling pixantrone, and the risk factors listed or described from time to time in the Company's filings with the Securities and Exchange Commission including, without limitation, the Company's most recent filings on Forms 10-K, 8-K, and 10-Q. Except as may be required by law, CTI does not intend to update or alter its forward-looking statements whether as a result of new information, future events, or otherwise.
Media Contact: Dan Eramian T: 206.272.4343 C: 206.854.1200 E: http://www.celltherapeutics.com/press_room
Investors Contact: Ed Bell T: 206.282.7100 Lindsey Jesch Logan T: 206.272.4347 F: 206.272.4434 E: http://www.celltherapeutics.com/investors
DATASOURCE: Cell Therapeutics, Inc.
CONTACT: Media, Dan Eramian, +1-206-272-4343, cell, +1-206-854-1200,
, or Investors, Ed Bell, +1-206-282-7100, or Lindsey Jesch
Logan, +1-206-272-4347, fax, +1-206-272-4434, , all of
Cell Therapeutics, Inc.
Web site: http://www.celltherapeutics.com/